Our Pricing

Understanding Wegovy Side Effects With WEIGHTLOSSNEW Savings

Published on: June 03, 2026

Understanding wegovy side effects uk is essential before starting semaglutide treatment. At Cured Pharmacy, our UK-registered clinical team has supported thousands of patients through their weight loss journey, and we've seen firsthand that most side effects are manageable with the right guidance. Wegovy is available from £79.00 with a free clinical assessment, and our superintendent pharmacist Tarun Kumar ensures every patient receives personalised advice on minimising discomfort whilst maximising results.

Most Common Wegovy Side Effects UK Patients Experience

In the STEP clinical trial programme involving over 4,500 participants, gastrointestinal side effects were the most frequently reported reactions to semaglutide [1]. Nausea affected approximately 44% of participants, whilst vomiting occurred in 24%, and diarrhoea in 30% of those receiving the highest maintenance dose [1]. These effects typically emerge during dose escalation and diminish as your body adapts to the medication.

Most patients find these symptoms are mild to moderate in severity and resolve within the first 8-12 weeks of treatment [2]. The graduated dosing schedule used with Wegovy — starting at 0.25mg weekly and slowly increasing over 16 weeks — is specifically designed to minimise gastrointestinal discomfort whilst allowing your digestive system time to adjust.

Other commonly reported side effects include constipation (affecting around 24% of participants), abdominal pain, headache, and fatigue [1]. Injection site reactions such as redness, itching, or mild swelling occur in fewer than 5% of patients and typically resolve without intervention within 2-3 days.

How to Manage Wegovy Nausea and Digestive Discomfort

Nausea management is the most common concern our clinical team addresses during follow-up consultations. The key is understanding that semaglutide slows gastric emptying — meaning food stays in your stomach longer, which contributes to feelings of fullness but can also trigger nausea if you overeat [3].

Practical strategies that have proven effective for our patients include eating smaller, more frequent meals rather than three large ones, avoiding high-fat foods which take longer to digest, and stopping eating as soon as you feel comfortably satisfied rather than full. Staying well-hydrated throughout the day and avoiding lying down immediately after meals can also significantly reduce nausea.

If nausea persists despite these measures, your UK prescriber may recommend temporarily pausing dose escalation or, in rare cases, stepping back to the previous dose until symptoms resolve. Anti-nausea medications are rarely needed but can be prescribed if symptoms significantly affect your quality of life.

Dietary Adjustments That Reduce Side Effects

Our clinical experience shows that patients who adopt specific dietary patterns experience fewer gastrointestinal side effects. Focus on lean proteins, whole grains, and vegetables whilst limiting processed foods, carbonated drinks, and high-sugar items. Eating slowly and chewing thoroughly allows your brain to register satiety signals before you've overeaten, which is particularly important given semaglutide's effect on gastric emptying [3].

Serious Wegovy Side Effects: When to Seek Medical Attention

Whilst most side effects are manageable, certain symptoms require immediate medical attention. Severe, persistent abdominal pain — particularly if accompanied by nausea and vomiting — may indicate pancreatitis, a rare but serious condition reported in approximately 0.2% of semaglutide users in clinical trials [1]. If you experience intense upper abdominal pain radiating to your back, contact your GP or NHS 111 immediately.

Symptoms of thyroid tumours, though extremely rare in humans, include a lump or swelling in your neck, persistent hoarseness, difficulty swallowing, or shortness of breath. The MHRA requires this warning based on animal studies, though no causal relationship has been established in human trials [4]. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Allergic reactions to semaglutide are uncommon but possible. Seek emergency care if you develop facial swelling, difficulty breathing, severe rash, or rapid heartbeat after injection. Hypoglycaemia (low blood sugar) is rare in patients without diabetes but can occur — symptoms include shakiness, sweating, confusion, and dizziness.

Gallbladder Issues and Rapid Weight Loss

Rapid weight loss from any cause increases the risk of gallstone formation, and this applies to patients using Wegovy [2]. Symptoms of gallbladder problems include severe pain in the upper right abdomen, particularly after eating fatty meals, along with nausea, vomiting, or yellowing of the skin or eyes. If you experience these symptoms, contact your healthcare provider for assessment.

Wegovy Side Effects vs Other Weight Loss Treatments

Understanding how Wegovy's side effect profile compares to other UK-licensed weight loss medications helps set realistic expectations. Orlistat, an alternative oral treatment, works by blocking fat absorption and commonly causes oily stools, faecal urgency, and flatulence — effects that many patients find more socially disruptive than Wegovy's nausea [5].

Saxenda (liraglutide), another GLP-1 receptor agonist requiring daily injections, has a similar side effect profile to Wegovy but typically produces less weight loss in clinical trials [6]. The once-weekly convenience of Wegovy often leads to better adherence and fewer injection site reactions compared to daily alternatives.

Newer dual-action medications show promise but aren't yet widely available through all UK pharmacies. Each treatment requires individual assessment by a UK prescriber who will consider your medical history, current medications, and personal preferences when recommending the most suitable option.

Long-Term Safety Profile of Semaglutide for Weight Loss

The STEP trials followed participants for up to 68 weeks, providing substantial data on semaglutide's long-term safety profile [1][2]. Discontinuation rates due to adverse events were 7.0% in the semaglutide group compared to 3.1% in the placebo group — meaning the vast majority of patients tolerated the medication well enough to continue treatment throughout the study period [1].

Cardiovascular safety data from the SELECT trial, which followed over 17,000 participants with pre-existing cardiovascular disease, demonstrated that semaglutide did not increase cardiovascular risk and may actually provide protective benefits [7]. This is particularly relevant for patients with obesity-related comorbidities such as hypertension or high cholesterol.

Our superintendent pharmacist Tarun Kumar emphasises that whilst Wegovy has an established safety profile, all prescription medications require ongoing monitoring. Your UK prescriber will schedule follow-up consultations to assess your response, adjust dosing if needed, and ensure you're achieving weight loss goals whilst maintaining good tolerability.

What Happens When You Stop Taking Wegovy

Clinical trial data shows that most patients regain some weight after discontinuing semaglutide, though lifestyle modifications adopted during treatment can help maintain results [2]. Side effects typically resolve within days to weeks of stopping the medication. If you're considering discontinuing Wegovy, discuss this with your prescriber rather than stopping abruptly, as they can provide guidance on transitioning to maintenance strategies.

Starting Wegovy Safely: What to Expect in Your First Month

Your first month on Wegovy involves the 0.25mg starter dose, which is sub-therapeutic for weight loss but essential for minimising side effects [1]. During this period, you may notice mild appetite reduction and possibly some nausea, particularly 1-3 days after your weekly injection. This is completely normal and indicates the medication is working.

Before your first injection, your UK prescriber will review your medical history to identify any contraindications. Wegovy is not suitable for patients with a history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Pregnancy must be excluded before starting treatment, and effective contraception is required throughout, as semaglutide's safety in pregnancy hasn't been established [4].

At Cured Pharmacy, your clinical assessment takes under 3 minutes to complete online, and our UK-registered prescribers review every submission individually. If approved, your Wegovy pen ships in 100% discreet packaging with full injection instructions. Our team remains available throughout your treatment journey to address concerns, adjust dosing schedules, or provide additional support as needed.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Nauck, M. A., et al. (2021). GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes – State-of-the-Art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
5. Torgerson, J. S., et al. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine that must be prescribed following an online consultation with our UK-registered clinical team. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.